Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the
“Company” or “Burning Rock”), a company focused on the application
of next generation sequencing (NGS) technology in the field of
precision oncology, today reported financial results for the three
months ended June 30, 2024.
Recent Business Updates
-
Therapy Selection
-
Presented study results on small-cell lung cancer and colorectal
cancer at the ASCO in June 2024. “The efficacy and safety of high
dose Almonertinib in untreated EGFR-mutated NSCLC with brain
metastases, including biomarker analysis” and “Individualized
tumor-informed circulating tumor DNA analysis for molecular
residual disease detection in predicting recurrence and efficacy of
adjuvant chemotherapy in colorectal cancer”.
-
Pharma Services
-
New companion diagnostics (CDx) collaboration announced with Bayer
in China.
Second Quarter 2024 Financial
Results
Total Revenues were RMB135.5 million (US$18.7
million) for the three months ended June 30, 2024, representing a
7.3% decrease from RMB146.3 million for the same period in 2023, as
we transition from central-lab to more in-hospital based testing.
Importantly, in-hospital segment continued its double-digit
growth.
-
Revenue generated from in-hospital business was RMB59.9 million
(US$8.2 million) for the three months ended June 30, 2024,
representing a 11.2% increase from RMB53.8 million for the same
period in 2023, driven by an increase in sales volume.
-
Revenue generated from central laboratory business was RMB48.8
million (US$6.7 million) for the three months ended June 30, 2024,
representing a 26.4% decrease from RMB66.2 million for the same
period in 2023, primarily attributable to a decrease in the number
of tests, as we continued our transition towards in-hospital
testing.
-
Revenue generated from pharma research and development services was
RMB26.9 million (US$3.7 million) for the three months ended June
30, 2024, representing a 2.6% increase from RMB26.2 million for the
same period in 2023, primarily attributable to an increased
development and testing services performed for our pharma
customers.
Cost of revenues was RMB40.1 million (US$5.5
million) for the three months ended June 30, 2024, representing an
12.5% decrease from RMB45.8 million for the same period in 2023,
primarily due to (i) a decrease in cost of central laboratory
business, which was in line with the decrease in revenue generated
from this business; and (ii) a decrease in amortization expense for
all kinds of business.
Gross profit was RMB95.4 million (US$13.1
million) for the three months ended June 30, 2024, representing a
5.0% decrease from RMB100.4 million for the same period in 2023.
Gross margin was 70.4% for the three months ended June 30, 2024,
compared to 68.7% for the same period in 2023. By channel, gross
margin of central laboratory business was 78.8% for the three
months ended June 30, 2024, compared to 78.3% during the same
period in 2023; gross margin of in-hospital business was 73.6% for
the three months ended June 30, 2024, compared to 62.0% during the
same period in 2023, primarily due to a decrease in amortization;
gross margin of pharma research and development services was 48.2%
for the three months ended June 30, 2024, compared to 58.0% during
the same period of 2023, primarily due to a decrease in test volume
of higher margin projects.
Non-GAAP gross profit, which excludes
depreciation and amortization expenses, was RMB101.9 million
(US$14.0 million) for the three months ended June 30, 2024,
representing a 6.8% decrease from RMB109.4 million for the same
period in 2023. Non-GAAP gross margin was 75.2% for the three
months ended June 30, 2024, compared to 74.8% for the same period
in 2023.
Operating expenses were RMB206.7 million
(US$28.4 million) for the three months ended June 30, 2024,
representing a 12.5% decrease from RMB236.1 million for the same
period in 2023. The decrease was primarily driven by budget control
measures and headcount reduction to improve the Company’s operating
efficiency.
-
Research and development expenses were RMB65.0 million (US$8.9
million) for the three months ended June 30, 2024, representing a
32.2% decrease from RMB95.8 million for the same period in 2023,
primarily due to (i) a decrease in staff cost resulted from the
reorganization of our research and development department to
improve operating efficiency; (ii) a decrease in the expenditure
for research projects; and (iii) a decrease in amortized expenses
for office building decoration.
-
Selling and marketing expenses were RMB48.9 million (US$6.7
million) for the three months ended June 30, 2024, representing a
31.0% decrease from RMB70.8 million for the same period in 2023,
primarily due to (i) a decrease in staff cost resulted from the
reorganization of the sales department and improvement in operating
efficiency; (ii) a decrease in conference fee; and (iii) a decrease
in travel expense.
-
General and administrative expenses were RMB92.8 million (US$12.8
million) for the three months ended June 30, 2024, representing a
33.5% increase from RMB69.5 million for the same period in 2023,
primarily due to an increase in amortized expense on share-based
compensation.
Net loss was RMB108.0 million (US$14.9 million)
for the three months ended June 30, 2024, compared to RMB131.2
million for the same period in 2023.
Cash, cash equivalents, restricted cash and
short-term investments were RMB533.0 million (US$73.3 million) as
of June 30, 2024.
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR and
LSE: BNR), whose mission is to guard life via science, focuses on
the application of next generation sequencing (NGS) technology in
the field of precision oncology. Its business consists of i)
NGS-based therapy selection testing for late-stage cancer patients,
and ii) cancer early detection, which has moved beyond
proof-of-concept R&D into the clinical validation stage.
For more information about Burning Rock, please
visit: ir.brbiotech.com.
Safe Harbor Statement
This press release contains forward-looking
statements. These statements constitute “forward-looking”
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and as defined in the U.S.
Private Securities Litigation Reform Act of 1995. These
forward-looking statements can be identified by terminology such as
“will,” “expects,” “anticipates,” “future,” “intends,” “plans,”
“believes,” “estimates,” “target,” “confident” and similar
statements. Burning Rock may also make written or oral
forward-looking statements in its periodic reports to the SEC, in
its annual report to shareholders, in press releases and other
written materials and in oral statements made by its officers,
directors or employees to third parties. Statements that are not
historical facts, including statements about Burning Rock’s beliefs
and expectations, are forward-looking statements. Such statements
are based upon management’s current expectations and current market
and operating conditions, and relate to events that involve known
or unknown risks, uncertainties and other factors, all of which are
difficult to predict and many of which are beyond Burning Rock’s
control. Forward-looking statements involve risks, uncertainties
and other factors that could cause actual results to differ
materially from those contained in any such statements. All
information provided in this press release is as of the date of
this press release, and Burning Rock does not undertake any
obligation to update any forward-looking statement as a result of
new information, future events or otherwise, except as required
under applicable law.
Non-GAAP Measures
In evaluating the business, the Company
considers and uses non-GAAP measures, such as non-GAAP gross profit
and non-GAAP gross margin, as supplemental measures to review and
assess operating performance. The presentation of these non-GAAP
financial measures is not intended to be considered in isolation or
as a substitute for the financial information prepared and
presented in accordance with accounting principles generally
accepted in the United States of America (“U.S. GAAP”). The company
defines non-GAAP gross profit as gross profit excluding
depreciation and amortization. The company defines non-GAAP gross
margin as gross margin excluding depreciation and amortization.
The company presents these non-GAAP financial
measures because they are used by management to evaluate operating
performance and formulate business plans. The company believe
non-GAAP gross profit and non-GAAP gross margin excluding non-cash
impact of depreciation and amortization reflect the company’s
ongoing business operations in a manner that allows more meaningful
period-to-period comparisons.
Contact: IR@brbiotech.com
Selected Operating Data
| |
As of |
|
|
June 30,2023 |
|
September 30, 2023 |
|
December 31, 2023 |
|
March 31, 2024 |
|
June 30, 2024 |
|
| In-hospital
Channel: |
|
|
|
|
|
|
|
|
|
|
| Pipeline partner
hospitals(1) |
30 |
|
29 |
|
28 |
|
28 |
|
29 |
|
| Contracted partner
hospitals(2) |
50 |
|
55 |
|
59 |
|
59 |
|
59 |
|
| Total number of
partner hospitals |
80 |
|
84 |
|
87 |
|
87 |
|
88 |
|
|
(1) |
|
Refers to hospitals that are in the process of establishing
in-hospital laboratories, laboratory equipment procurement or
installation, staff training or pilot testing using the Company’s
products. |
| (2) |
|
Refers to hospitals that have
entered into contracts to purchase the Company’s products for use
on a recurring basis in their respective in-hospital laboratories
the Company helped them establish. Kit revenue is generated from
contracted hospitals. |
Selected Financial Data
| |
For the three
months ended |
| Revenues |
June 30, 2023 |
|
September 30, 2023 |
|
December 31, 2023 |
|
March 31, 2024 |
|
June 30, 2024 |
|
| |
(RMB in thousands) |
| Central laboratory channel |
66,239 |
|
53,481 |
|
51,288 |
|
47,614 |
|
48,773 |
|
| In-hospital channel |
53,835 |
|
54,496 |
|
28,809 |
|
57,387 |
|
59,872 |
|
| Pharma research and development
channel |
26,194 |
|
19,589 |
|
40,988 |
|
20,622 |
|
26,888 |
|
| Total
revenues |
146,268 |
|
127,566 |
|
121,085 |
|
125,623 |
|
135,533 |
|
| |
|
|
|
|
|
|
|
|
| |
For the three
months ended |
| Gross
profit |
June 30, 2023 |
|
September 30, 2023 |
|
December31, 2023 |
|
March 31, 2024 |
|
June 30, 2024 |
|
| |
(RMB in thousands) |
| Central laboratory channel |
51,876 |
|
41,487 |
|
41,886 |
|
37,002 |
|
38,424 |
|
| In-hospital channel |
33,353 |
|
35,459 |
|
12,910 |
|
39,192 |
|
44,058 |
|
| Pharma research and development
channel |
15,193 |
|
8,974 |
|
23,317 |
|
9,500 |
|
12,956 |
|
| Total gross
profit |
100,422 |
|
85,920 |
|
78,113 |
|
85,694 |
|
95,438 |
|
| |
|
|
|
|
|
|
|
|
| |
For the three months
ended |
| Share-based
compensation expenses |
June 30,2023 |
|
September 30, 2023 |
|
December31, 2023 |
|
March 31, 2024 |
|
June 30, 2024 |
|
|
| |
(RMB in
thousands) |
| Cost of revenues |
627 |
|
680 |
|
654 |
|
596 |
|
464 |
|
|
| Research and development
expenses |
15,301 |
|
12,161 |
|
12,401 |
|
12,287 |
|
12,008 |
|
|
| Selling and marketing
expenses |
3,389 |
|
2,848 |
|
1,816 |
|
508 |
|
1,232 |
|
|
| General and administrative
expenses |
18,502 |
|
57,704 |
|
56,472 |
|
55,990 |
|
54,407 |
|
|
| Total share-based
compensation expenses |
37,819 |
|
73,393 |
|
71,343 |
|
69,381 |
|
68,111 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
Burning Rock Biotech Limited
Unaudited Condensed Statements of Comprehensive
Loss (in thousands, except for number of shares and per
share data)
| |
For the three months ended |
|
|
June 30, 2023 |
|
September 30, 2023 |
|
December 31,2023 |
|
March 31, 2024 |
|
June 30, 2024 |
|
June 30, 2024 |
|
| |
RMB |
RMB |
|
RMB |
|
RMB |
|
RMB |
|
US$ |
|
|
Revenues |
146,268 |
|
127,566 |
|
121,085 |
|
125,623 |
|
135,533 |
|
18,650 |
|
| Cost of
revenues |
(45,846) |
|
(41,646) |
|
(42,972) |
|
(39,929) |
|
(40,095) |
|
(5,517) |
|
| Gross
profit |
100,422 |
|
85,920 |
|
78,113 |
|
85,694 |
|
95,438 |
|
13,133 |
|
| Operating
expenses: |
|
|
|
|
|
|
|
| Research and development
expenses |
(95,779) |
|
(83,701) |
|
(73,119) |
|
(65,985) |
|
(64,952) |
|
(8,938) |
|
| Selling and marketing
expenses |
(70,842) |
|
(62,310) |
|
(49,785) |
|
(46,856) |
|
(48,907) |
|
(6,730) |
|
| General and administrative
expenses |
(69,525) |
|
(118,724) |
|
(121,533) |
|
(98,681) |
|
(92,794) |
|
(12,769) |
|
| Total operating
expenses |
(236,146) |
|
(264,735) |
|
(244,437) |
|
(211,522) |
|
(206,653) |
|
(28,437) |
|
| Loss from
operations |
(135,724) |
|
(178,815) |
|
(166,324) |
|
(125,828) |
|
(111,215) |
|
(15,304) |
|
| Interest income |
5,255 |
|
4,018 |
|
5,539 |
|
4,038 |
|
3,187 |
|
439 |
|
| Other income (expense),
net |
(118) |
|
(157) |
|
160 |
|
434 |
|
(82) |
|
(11) |
|
| Foreign exchange (loss) gain,
net |
（210) |
|
423 |
|
(517) |
|
(13) |
|
262 |
|
36 |
|
| Loss before income
tax |
(130,797) |
|
(174,531) |
|
(161,142) |
|
(121,369) |
|
(107,848) |
|
(14,840) |
|
| Income tax expenses |
(445) |
|
(450) |
|
(1,071) |
|
(180) |
|
(190) |
|
(26) |
|
| Net loss |
(131,242) |
|
(174,981) |
|
(162,213) |
|
(121,549) |
|
(108,038) |
|
(14,866) |
|
| Net loss attributable
to Burning Rock Biotech Limited’s shareholders |
(131,242) |
|
(174,981) |
|
(162,213) |
|
(121,549) |
|
(108,038) |
|
(14,866) |
|
| Net loss attributable
to ordinary shareholders |
(131,242) |
|
(174,981) |
|
(162,213) |
|
(121,549) |
|
(108,038) |
|
(14,866) |
|
| Loss per share for class
A and class B ordinary shares: |
|
|
|
|
|
|
|
| Class A ordinary shares - basic
and diluted |
(1.28) |
|
(1.71) |
|
(1.58) |
|
(1.19) |
|
(1.05) |
|
(0.14) |
|
| Class B ordinary shares - basic
and diluted |
(1.28) |
|
(1.71) |
|
(1.58) |
|
(1.19) |
|
(1.05) |
|
(0.14) |
|
| Weighted average shares
outstanding used in loss per share computation: |
|
|
|
|
|
|
|
| Class A ordinary shares - basic
and diluted |
85,151,052 |
|
85,000,869 |
|
85,071,360 |
|
85,219,188 |
|
85,271,858 |
|
85,271,858 |
|
| Class B ordinary shares - basic
and diluted |
17,324,848 |
|
17,324,848 |
|
17,324,848 |
|
17,324,848 |
|
17,324,848 |
|
17,324,848 |
|
| Other comprehensive
income (loss), net of tax of nil: |
|
|
|
|
|
|
|
| Foreign currency translation
adjustments |
14,829 |
|
(1,955) |
|
(3,026) |
|
590 |
|
940 |
|
129 |
|
| Total comprehensive
loss |
(116,413) |
|
(176,936 ) |
|
(165,239) |
|
(120,959 ) |
|
(107,098) |
|
(14,737) |
|
| Total comprehensive loss
attributable to Burning Rock Biotech Limited’s
shareholders |
(116,413) |
|
(176,936) |
|
(165,239) |
|
(120,959 ) |
|
(107,098) |
|
(14,737) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Burning Rock Biotech Limited
Unaudited Condensed Statements of Comprehensive
Loss (in thousands, except for number of shares and per
share data)
| |
For the six months ended |
| |
June 30, 2023 |
|
June 30, 2024 |
|
June 30, 2024 |
|
| |
RMB |
|
RMB |
|
US$ |
|
|
Revenues |
288,784 |
|
261,156 |
|
35,937 |
|
| Cost of
revenues |
(89,590) |
|
(80,024) |
|
(11,012) |
|
| Gross
profit |
199,194 |
|
181,132 |
|
24,925 |
|
| Operating
expenses: |
|
|
|
| Research and development
expenses |
(190,196) |
|
(130,937) |
|
(18,018) |
|
| Selling and marketing
expenses |
(135,616) |
|
(95,763) |
|
(13,177) |
|
| General and administrative
expenses |
(197,564) |
|
(191,475) |
|
(26,349) |
|
| Total operating
expenses |
(523,376) |
|
(418,175) |
|
(57,544) |
|
| Loss from
operations |
(324,182) |
|
(237,043) |
|
(32,619) |
|
| Interest income |
8,399 |
|
7,225 |
|
994 |
|
| Other income, net |
481 |
|
352 |
|
48 |
|
| Foreign exchange loss,
net |
(326) |
|
249 |
|
34 |
|
| Loss before income
tax |
(315,628) |
|
(229,217) |
|
(31,543) |
|
| Income tax expenses |
(867) |
|
(370) |
|
(51) |
|
| Net loss |
(316,495) |
|
(229,587) |
|
(31,594) |
|
| Net loss attributable
to Burning Rock Biotech Limited’s shareholders |
(316,495) |
|
(229,587) |
|
(31,594) |
|
| Net loss attributable
to ordinary shareholders |
(316,495) |
|
(229,587) |
|
(31,594) |
|
| Loss per share for class
A and class B ordinary shares: |
|
|
|
| Class A ordinary shares - basic
and diluted |
(3.09) |
|
(2.24) |
|
(0.31) |
|
| Class B ordinary shares - basic
and diluted |
(3.09) |
|
(2.24) |
|
(0.31) |
|
| Weighted average shares
outstanding used in loss per share computation: |
|
|
|
| Class A ordinary shares - basic
and diluted |
85,108,555 |
|
85,246,969 |
|
85,246,969 |
|
| Class B ordinary shares - basic
and diluted |
17,324,848 |
|
17,324,848 |
|
17,324,848 |
|
| Other comprehensive
income (loss), net of tax of nil: |
|
|
|
| Foreign currency translation
adjustments |
9,170 |
|
1,530 |
|
211 |
|
| Total comprehensive
loss |
(307,325) |
|
(228,057) |
|
(31,383) |
|
| Total comprehensive loss
attributable to Burning Rock Biotech Limited’s
shareholders |
(307,325) |
|
(228,057) |
|
(31,383) |
|
|
|
|
|
|
|
|
|
Burning Rock Biotech
LimitedUnaudited Condensed Consolidated Balance
Sheets(In thousands)
| |
As of |
|
|
December 31, 2023 |
|
June 30,2024 |
|
June 30,2024 |
|
| |
RMB |
|
RMB |
|
US$ |
|
| ASSETS |
|
|
|
|
|
|
| Current
assets: |
|
|
|
|
|
|
| Cash and cash equivalents |
615,096 |
|
532,542 |
|
73,280 |
|
| Restricted cash |
120 |
|
505 |
|
69 |
|
| Accounts receivable, net |
126,858 |
|
153,641 |
|
21,142 |
|
| Contract assets, net |
22,748 |
|
20,018 |
|
2,755 |
|
| Inventories, net |
69,020 |
|
65,805 |
|
9,056 |
|
| Prepayments and other current
assets, net |
50,254 |
|
28,460 |
|
3,916 |
|
| Convertible note
receivable |
- |
|
5,320 |
|
732 |
|
| Total current
assets |
884,096 |
|
806,291 |
|
110,950 |
|
| Non-current
assets: |
|
|
|
|
|
|
| Equity method investment |
337 |
|
247 |
|
34 |
|
| Convertible note
receivable |
5,320 |
|
- |
|
- |
|
| Property and equipment,
net |
131,912 |
|
100,716 |
|
13,860 |
|
| Operating right-of-use
assets |
12,284 |
|
105,429 |
|
14,508 |
|
| Intangible assets, net |
964 |
|
724 |
|
100 |
|
| Other non-current assets |
5,088 |
|
9,976 |
|
1,372 |
|
| Total non-current
assets |
155,905 |
|
217,092 |
|
29,874 |
|
| TOTAL
ASSETS |
1,040,001 |
|
1,023,383 |
|
140,824 |
|
|
|
|
|
|
|
|
|
Burning Rock Biotech
LimitedUnaudited Condensed Consolidated Balance
Sheets (Continued)(in thousands)
| |
As of |
| |
December 31, 2023 |
|
June 30,2024 |
|
June 30,2024 |
|
| |
RMB |
RMB |
US$ |
| LIABILITIES AND
SHAREHOLDERS’ EQUITY |
|
|
|
| Current
liabilities: |
|
|
|
|
Accounts payable |
18,061 |
|
25,870 |
|
3,560 |
|
| Deferred revenue |
130,537 |
|
119,352 |
|
16,423 |
|
| Accrued liabilities and other
current liabilities |
104,935 |
|
86,300 |
|
11,876 |
|
| Customer deposits |
1,197 |
|
1,197 |
|
165 |
|
| Current portion of operating
lease liabilities |
8,634 |
|
26,922 |
|
3,705 |
|
| Total current
liabilities |
263,364 |
|
259,641 |
|
35,729 |
|
| Non-current
liabilities: |
|
|
|
| Non-current portion of
operating lease liabilities |
3,690 |
|
80,988 |
|
11,144 |
|
| Other non-current
liabilities |
4,537 |
|
4,908 |
|
676 |
|
| Total non-current
liabilities |
8,227 |
|
85,896 |
|
11,820 |
|
| TOTAL
LIABILITIES |
271,591 |
|
345,537 |
|
47,549 |
|
| Shareholders’
equity: |
|
|
|
| Class A ordinary shares |
116 |
|
116 |
|
16 |
|
| Class B ordinary shares |
21 |
|
21 |
|
3 |
|
| Additional paid-in
capital |
4,849,337 |
|
4,986,830 |
|
686,211 |
|
| Treasury stock |
(65,896) |
|
(65,896) |
|
(9,068) |
|
| Accumulated deficits |
(3,853,635) |
|
(4,083,222) |
|
(561,870) |
|
| Accumulated other
comprehensive loss |
(161,533) |
|
(160,003) |
|
(22,017) |
|
| Total shareholders’
equity |
768,410 |
|
677,846 |
|
93,275 |
|
| TOTAL LIABILITIES AND
SHAREHOLDERS’ EQUITY |
1,040,001 |
|
1,023,383 |
|
140,824 |
|
|
|
|
|
|
|
|
|
Burning Rock Biotech
LimitedUnaudited Condensed Statements of Cash
Flows(in thousands)
| |
For the three months ended |
|
|
June 30, 2023 |
|
June 30,2024 |
|
June 30,2024 |
|
| |
RMB |
RMB |
US$ |
| Net cash used in operating
activities |
(79,204) |
|
(40,836) |
|
(5,619) |
|
| Net cash used in investing
activities |
(2,928) |
|
(227) |
|
(31) |
|
| Net cash used in financing
activities |
(1,003) |
|
- |
|
- |
|
| Effect of exchange rate on
cash, cash equivalents and restricted cash |
13,271 |
|
1,436 |
|
196 |
|
| Net decrease in cash,
cash equivalents and restricted cash |
(69,864) |
|
(39,627) |
|
(5,454) |
|
| Cash, cash equivalents and
restricted cash at the beginning of period |
803,142 |
|
572,674 |
|
78,803 |
|
| Cash, cash equivalents
and restricted cash at the end of period |
733,278 |
|
533,047 |
|
73,349 |
|
| |
|
| |
For the six months ended |
|
|
June 30,2023 |
|
June 30,2024 |
|
June 30,2024 |
|
| |
RMB |
RMB |
US$ |
|
Net cash used in operating activities |
(192,347) |
|
(81,045) |
|
(11,152) |
|
| Net cash used in investing
activities |
(6,987) |
|
(2,613) |
|
(360) |
|
| Net cash used in financing
activities |
(1,035) |
|
- |
|
- |
|
| Effect of exchange rate on
cash, cash equivalents and restricted cash |
8,379 |
|
1,489 |
|
204 |
|
| Net decrease in cash,
cash equivalents and restricted cash |
(191,990) |
|
(82,169) |
|
(11,308) |
|
| Cash, cash equivalents and
restricted cash at the beginning of period |
925,268 |
|
615,216 |
|
84,657 |
|
| Cash, cash equivalents
and restricted cash at the end of period |
733,278 |
|
533,047 |
|
73,349 |
|
| |
|
Burning Rock Biotech
LimitedReconciliations of GAAP and Non-GAAP
Results
| |
For the three months ended |
|
|
June 30,2023 |
|
September 30, 2023 |
|
December 31, 2023 |
|
March 31,2024 |
|
June 30,2024 |
|
| |
(RMB in thousands) |
| Gross
profit: |
|
|
| Central laboratory channel |
51,876 |
|
41,487 |
|
41,886 |
|
37,002 |
|
38,424 |
|
| In-hospital channel |
33,353 |
|
35,459 |
|
12,910 |
|
39,192 |
|
44,058 |
|
| Pharma research and development
channel |
15,193 |
|
8,974 |
|
23,317 |
|
9,500 |
|
12,956 |
|
| Total gross
profit |
100,422 |
|
85,920 |
|
78,113 |
|
85,694 |
|
95,438 |
|
| Add: depreciation and
amortization: |
|
|
|
|
|
| Central laboratory channel |
2,645 |
|
2,550 |
|
2,414 |
|
1,919 |
|
1,226 |
|
| In-hospital channel |
2,637 |
|
2,751 |
|
2,728 |
|
1,524 |
|
824 |
|
| Pharma research and development
channel |
3,665 |
|
3,863 |
|
3,808 |
|
3,856 |
|
4,417 |
|
| Total depreciation and
amortization included in cost of revenues |
8,947 |
|
9,164 |
|
8,950 |
|
7,299 |
|
6,467 |
|
| Non-GAAP gross
profit： |
|
|
|
|
|
| Central laboratory channel |
54,521 |
|
44,037 |
|
44,300 |
|
38,921 |
|
39,650 |
|
| In-hospital channel |
35,990 |
|
38,210 |
|
15,638 |
|
40,716 |
|
44,882 |
|
| Pharma research and development
channel |
18,858 |
|
12,837 |
|
27,125 |
|
13,356 |
|
17,373 |
|
| Total non-GAAP gross
profit |
109,369 |
|
95,084 |
|
87,063 |
|
92,993 |
|
101,905 |
|
| Non-GAAP gross
margin： |
|
|
|
|
|
| Central laboratory channel |
82.3% |
|
82.3% |
|
86.4% |
|
81.7% |
|
81.3% |
|
| In-hospital channel |
66.9% |
|
70.1% |
|
54.3% |
|
70.9% |
|
75.0% |
|
| Pharma research and development
channel |
72.0% |
|
65.5% |
|
66.2% |
|
64.8% |
|
64.6% |
|
| Total non-GAAP gross
margin |
74.8% |
|
74.5% |
|
71.9% |
|
74.0% |
|
75.2% |
|
Burning Rock Biotech (NASDAQ:BNR)
Historical Stock Chart
From Nov 2024 to Dec 2024
Burning Rock Biotech (NASDAQ:BNR)
Historical Stock Chart
From Dec 2023 to Dec 2024
